GHRS GH Research PLC
GH Research PLC (GHRS) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.27 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.5% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company. It dedicated to treat psychiatric and neurological disorders. The company's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression. GH Research PLC is based in DUBLIN.
Sector
Healthcare
Industry
Biotechnology